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Background: Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant inherited endocrine
malignancy syndrome. Early and normative surgery is the only curative method for MEN 2-related medullary thyroid
carcinoma (MTC). In patients with adrenal pheochromocytoma, cortical-sparing adrenalectomy (CSA) can be utilized
to preserve adrenocortical function.
Methods: We present twenty-six of 33 MEN2 patients underwent prophylactic thyroidectomy with varying neck
dissection and eight of 24 MEN2A patients with PHEO underwent adrenal-sparing surgery. Direct sequencing of
entire RET exons was performed in all participants.
Results: The RET mutations (p.C634Y [n = 10], p.C634R [n = 9], p.C634F [n = 2], p.C618Y [n = 8], p.C618R [n = 3], and
p.M918T [n = 1]) were confirmed in 20 symptomatic patients and identified in 13 at-risk relatives (RET carriers).
Twenty-six of 33 MEN2 patients underwent thyroidectomies with neck dissections; the mean age at the time of the
first thyroid surgery and the tumor diameter of the 6 RET carriers was decreased compared with 20 symptomatic
patients (P < 0.001 and P = 0.007, respectively), while the disease-free survival was increased (80% vs.10%, P = 0.0001).
Seven RET carriers who were declined surgery. One of 20 symptomatic patients with MTC bone metastases after surgery
received vandetanib therapy for 20 months and responded well. Additionally, 8 of 24 MEN2A patients who initially had
unilateral pheochromocytomas underwent CSA, 1 developed contralateral pheochromo cytomas 10 years later, then
also accepted and also agreed to a CSA. None of the patients required steroid replacement therapy.
Conclusions: Based on our results, integrated RET screening and the pre-operative calcitonin level is an excellent strategy
to ensure earlier diagnosis and standard thyroidectomy. CSA can be utilized to preserve adrenocortical function in patients
with pheochromocytomas.
Keywords: Multiple endocrine neoplasia type 2, Mutation screening, RET, Prophylactic thyroidectomy, Cortical-sparing
adrenalectomyBackground
Multiple endocrine neoplasia type 2 (MEN2) is an auto-
somal dominant inherited endocrine malignancy syndrome,
with an occurrence of approximately 1 in 30 000; MEN2 is
due to germline mutations in the REarranged during
Transfection (RET) proto-oncogene (OMIM: 164761) [1,2],
which includes the following three subtypes: MEN2A* Correspondence: qxplmd@vip.sina.com
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unless otherwise stated.(OMIM: 171400); familial medullary thyroid cancer
(FMTC; OMIM: 155240); and MEN2B (OMIM: 162300)
[3]. MEN2A mainly consists of MTC, adrenal pheochromo-
cytoma (PHEO), and hyperparathyroidism (HPT). FMTC
presents clinically as MTC, but four or more persons in a
family or multiple generations must satisfy the diagnostic
criteria for MTC without other endocrine gland neoplasm
features [3,4]. MEN2B-related MTC has a higher invasive-
ness than MEN2A or FMTC, and often accompanies
PHEO, mucosal and gastrointestinal ganglioneuromas,
corneal nerve thickening (CNT), and Marfan’s body hab-
itus [5]. Of patients with MEN2, 95%-100% will develophis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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clinical symptoms usually present with lymph node metas-
tasis (LNM) in the third or fourth decade of life. Distant
metastases of MTC are the major cause of death [5-7].
MEN2 patients can be diagnosed early through system-
atic pedigree investigation and RET proto-oncogene
screening [3-5]. In the vast majority of cases, > 70 RET
mutations accumulate that are related to MEN2, and >
98% of RET mutations are located in exons 5, 8, 10, 11,
and 13–16 [4]. In 2009, the American Thyroid Association
(ATA) performed a timing prophylactic total thyroidec-
tomy (TT) procedure based on a model that utilized the
following genotype-phenotype correlations to stratify mu-
tations into four risk levels: ATA-A→D, A < B < C <D. It
was recommended that ATA-B and -C level mutation car-
riers should be considered for prophylactic TT, which
should be performed before 5 years of age. However, it has
been shown that family members with the same RET mu-
tation may have different clinical phenotypes or offspring
might exhibit earlier MTC phenotypes [4,5].
In recent years, combined detection of RET mutations
and pre-operative calcitonin (pre-Ct) levels have been con-
sidered for comprehensive decision-making regarding the
timing or surgical extent of prophylactic TT [8-11]. More-
over, phase III clinical trials have demonstrated that one
oral drug (such as vandetanib), which is a small molecular
multi-targeted tyrosine kinase inhibitor, provides a new
therapeutic choice for advanced hereditary MTC patients
whose disease cannot be resected or who present with
metastatic lesions [12]. Because most of the MEN2A-
related PHEO presentations are benign with bilateral mul-
tiple onsets, it is currently preferred to perform laparo-
scopic cortical-sparing adrenalectomy (CSA) [5,13,14].
In the present study, we report 33 MEN2 cases derived
from 9 unrelated MEN2 families residing in southeastern
China. Our aim was to analyze the feasibility of prophy-
lactic TT based on predictive integrated screening of
RET and pre-Ct levels. We also observed and evaluated
the efficacy and safety of vandetanib in the treatment of
one advanced case of MEN2A-MTC, and determined




Nine MEN2 families from Zhejiang Province of southeast-
ern China were recruited. All patients were diagnosed and
treated at the Zhejiang Cancer Hospital or the 117th PLA
Hospital between August 1989 and January 2013. System-
atic family screening was performed between 2005 and
2013, and comprehensive medical data, including clinical
profiles, surgical procedures, pre- and post-operative bio-
chemical data, and follow-up records were studied. The
patients diagnosed before 1993 were submitted to RETgenetic analysis at the time of family screening. All partici-
pants and/or their legal guardians provided written in-
formed consent, as required by the institution’s Ethical
Committee.
Clinical approach
All RET gene mutation carriers underwent biochemical
and imaging examinations to ascertain thyroid, parathy-
roid, and adrenal gland involvement. The biochemical
examination included Ct by chemiluminescence assay
(normal male, <8.4 ng/L; and female, <5.0 ng/L), parathy-
roid hormone (PTH) by electrochemical immunoassay,
carcinoembryonic antigen by chemiluminescence assay,
catecholamines, 3-methyl-4-hydroxy mandelic acid by
radioimmunoassay, serum calcium by the arsenazo III
method, and serum phosphate by UV molybdate. The im-
aging examinations included thyroid ultrasound/CT, ad-
renal gland and parathyroid gland nuclear magnetic
resonance (MRI), emission computed tomography (ECT),
and/or PET-CT scan assessments, if indicated.
Genetic testing
Genomic DNA was isolated from the peripheral blood
of 86 family members. The coding region of RET exons
5, 8, 10, 11, and 13–16 was amplified and sequenced in
sense and antisense directions with an ABI Prism 3730
automatic sequencer (Perkin-Elmer, USA).
Follow-up management
All patients were followed for evaluation of tumor recur-
rence and metastasis after surgery. Since 2005, the
standard follow-up for MTC has consisted of determin-
ing the Ct level, plasma calcium level (every 6 months),
and during the post-operative period under conditions
in which the Ct level is abnormal, a detailed imaging
examination may be considered (yearly). For MEN2A-
related PHEO patients, biochemical and imaging exami-
nations were repeated every 6–12 months, and life-time
follow-up was then required. For RET mutation carriers
without PHEOs, after initial screening at 20 years of age,
repeat biochemical and imaging examinations were per-
formed every year to screen for PHEOs and HPT [5].
Statistical analysis
All data were analyzed with SPSS (version 12.0) software.
We carried out univariate analysis using the Fisher’s exact
test. Student’s t-test was used to analyze differences be-
tween mean values.
Results
Clinical and diagnostic data
The 33 MEN2 patients consisted of 9 index-cases
(7 males and 2 females), 11 clinical patients (5 males
and 6 females) and 13 asymptomatic carriers (4 males
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38.6 ± 10.7 years (range, 23–58 years), 38.8 ± 16.6 years
(range, 20–65 years), and 30.0 ± 18.5 years (range, 9–78
years), respectively. All patients derived from 9 unrelated
MEN 2 families and harbored 1 of 6 heterozygous mis-
sense mutations; 7 families had MEN2A (p.C634Y [n = 3],
p.C634R [n = 2], p.C634F [n = 1], p.C618R [n = 1]), 1
family had FMTC (p.C618Y [n = 1]), and 1 family had
MEN2B (p.M918T [n = 1]). Of the 33 MEN2 patients, 32
(97%) were diagnosed with MTC (31) or C-cell hyperpla-
sia (1) and 8 (33.3%) were diagnosed with PHEO (Table 1
and Figure 1). None of the 33 MEN2 patients had con-
sistently evidence of any co-occurring related MEN2 clin-
ical symptoms (pruritic cutaneous lichen amyloidosis or
Hirschsprung’s disease), or HPT (serum PTH, Calcium or
PTH/calcium rates, and serum phosphate levels ranged in
all normal), except one MEN2B patient (F9-II3) had a
broad spectrum of pathognomonic nonendocrine abnor-
malities: a Marfanoid body habitus, tongue mucosal neur-
omas, lips hypertrophy and CNT.
Genogram MTC
Of the 33 MEN2 patients, 32 (97% [20 symptomatic pa-
tients including 9 index-cases and 11 clinical patients, and
12 asymptomatic carriers]) who were diagnosed with
MTC or C-cell hyperplasia (CCH) clinically or based on
pathologic evaluation, the mean diagnostic age was 34.6 ±
16.1 years; 1 RET-carrier (F8-III5) had no abnormalities.
Twenty symptomatic patients were admitted to the hos-
pital for neck masses or neck pain and diagnosed with
MTC before clinical screening. Thirteen of 20 (65%) pa-
tients were subjected to sub-standard thyroid surgery: 8
patients underwent interval (at least 2 times) TT and bilat-
eral VI region lymph node dissection [B-LND (VI)] or
modified bilateral cervical lymph node dissection (MBND);
3 patients underwent bilateral sub-TT and/or MBND; andTable 1 Clinical and molecular features of nine MEN2 families
Family Numbers of patients Sex ratio (M/F) Age range (years
MEN2A
F1 2 1/1 28-58
F2 1 1/0 35
F3 6 2/4 9-44
F4 3 2/1 18-44
F5 3 2/1 19-32
F6 6 4/2 19-65
F7 3 1/2 21-36
FMTC
F8 8 2/6 24-78
MEN2B
F9 1 1/0 332 patients underwent unilateral TT and B-LND (VI) with
MBND. The other 7 patients were accepted for standard
thyroid surgery, as follows: 5 patients underwent TT plus
B-LND (VI) plus MBND; and 2 patients underwent TT
plus B-LND (VI). The histopathologic results showed that
20 patients had bilateral MTC (1 patient with T2N0M0
and 19 patients with T1N1bM0 ~T3N1bM0; Table 2).
The median time of follow-up thus far is 115.6 ±
90.4 months (range, 21–384 months). The results of post-
Ct levels were normal in 2 patients (10% [T2N0M0 and
T1N1bM0]) and elevated in 18 patients (90%). Moreover,
2 of 20 patients (F6-II5 and F4-II1) had elevated Ct levels >
2000 ng/L. One patient (F6-II5), a 39-year-male-old with
T3N1bM0, underwent surgery successively 4 times and
eventually exhibited multiple bone metastases based on
ECT and MRI examinations 11 years after the initial sur-
gery. Vandetanib (ZD6474, Zactima™) was administered
orally at an initial dose of 300 mg/d; bone pain resolved
and the Ct levels decreased from 8755.3 ng/L to
873.6 ng/L after 2 months. Eight months later, the patient
appeared uncomfortable and distressed. An electrocardio-
gram showed Q-T interval prolongation and incomplete
right bundle branch block. Subsequently, the dose of van-
detanib was decreased from 300 mg to 200 mg once a day
for 20 months (until the present). The Ct level increased
to 5869.2 ng/L during therapy, while repeated PET-CT ex-
aminations failed to show any obvious advance bone
metastatic lesions. The patient developed erythema after
vandetanib therapy, but had no pruritus, headaches,
nausea, or reduction in the number of white blood cells.
The other patients (F4-II1), a 50-year-male-old with
T2N1bM0, declined further therapy and has survived with
the tumor in situ for 19 years (until the present; Table 2).
Thirteen asymptomatic RET carriers were confirmed by
clinical family screening, 12 of whom had elevated pre-Ct













Figure 1 Genealogy of seven MEN2A families (F1-F7), one FMTC family (F8) and one MEN2B family (F9).
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TT plus MBND (n = 1). The histopathologic examin-
ation revealed MTC in 5 patients (4 patients with
T1N0M0 and 1 patient with T1N1bM0) and 1 26-year-
old patient with CCH (F8-IV5; Table 3). The median
time of follow-up thus far has been 19.6 ± 3.2 months
(range, 17–26 months) and the results of post-Ct levels
were normal in 5 patients. Unfortunately, a 21-year-old
male (F6-III4) with T1N1bM0 still has an elevated Ct
level. In addition, the remaining 7 patients declined/
awaited surgery, 6 of whom had progressively increased
Ct levels, and only a 53-year-old male (F8-III5) has a
normal Ct level and no thyroid nodules based on im-
aging (Table 3).
The asymptomatic RET carriers who underwent sur-
gery benefited greatly from genetic screening and were a
significantly younger age at the time of surgery and had
a smaller tumor diameter compared with symptomatic
patients (P < 0.001 and P = 0.007, respectively). One RET
carrier had lymph node metastasis compared with 19 of
20 symptomatic patients (P = 0.0001). The disease-free
survival (DFS) increased in the asymptomatic RET car-
riers who underwent surgery compared to the symptom-
atic patients (80% vs. 10%, P = 0.0001; Table 2).PHEO
Of 24 MEN2A patients, 8 presented with PHEOs, includ-
ing 5 males and 3 females (7 p.C634Y/R/F and 1 p.C618R
RET-mutations) (Table 4). The mean age at the time of
diagnosis was 35.8 ± 9.2 years (range, 21–47 years).
Among 8 PHEO patients, 5 were symptomatic and 3 were
asymptomatic. The asymptomatic patients were diagnosed
during systematic pedigree analysis. In addition, all 8
PHEO patients initially presented with unilateral disease.
Unilateral CSA was initially performed, and 4 of 8 patients
underwent a laparoscopic technique. The average max-
imum diameter of the PHEOs was 3.9 ± 2.5 cm (range,
2.3-10.0 cm), and all of the PHEOs were located within
the adrenal glands. One patient (F5-II1) relapsed after ini-
tially developing a contralateral tumor after 10 years, and
underwent CSA on the opposite side (bilateral CSA). After
surgery, none of the 8 patients required steroid replace-
ment therapy. The median time of follow-up thus far has
been 88.3 ± 84.1 months (range, 8–252 months). There
were no surgical complications, such as hypoadrenalism,
Addison’s crisis, local recurrence, or distant metastasis.
Interestingly, the 58-year-old father (F1-I1) of a RET car-
rier (F1-II4) with unilateral PHEO and MTC in the F1
family had presented with MTC as the only clinical














Female patients 16 (48.5%) 7(35%) 9 (69.2%)
Genotype
p.C634F/Y/R 21 12 9
p.C 618Y/R 11 7 4





Age at first surgery,
mean (years)
34.6 ± 16.1 38.7 ± 13.9 20.7 ± 2.9 <0.001
TT with central and
lateral LND
14 13 1
TT with central LND 5 2 3
TT without LND 2 0 2




2.2 ± 1.2 2.6 ± 1.0 0.7 ± 0.4 0.007
CCH 1 0 1
MTC 25 20 5
Lymph node
metastasis
N0 6 1 5
N1 20 19 1 0.0001
Distant metastasis
M0 23 18 5
M1 2 2 0
Disease-free survival 6 2 4 0.0001
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the F6 family, the first (I) and second (II) generation also
had the only clinical manifestations of MTC, while only
one patient in their offspring (III-2) had evidence of a
PHEO.Follow-up management
Seven asymptomatic RET carriers were strictly moni-
tored and presented with gradually increasing Ct levels,
but did not undergo surgery. The other 26 patients re-
ceived thyroid hormone replacement therapy lifetime,
and were given calcium and vitamin D3 as preventive
supplements at least 1 year after surgery. Moreover, thy-
roid, adrenal, and parathyroid function was normal, with
no evidence of complications, such as tetany.RET germline variants
All 33 RET mutation-positive patients (consisting of 20
symptomatic patients and 13 asymptomatic RET car-
riers) harbored 1 of 6 heterozygous missense mutations
within exons 10 (p.C618Y [n = 8] and p.C618R [n = 3]),
11 (p.C634Y [n = 10], p.C634R [n = 9], and p.C634F [n =
2]), 16 (p.M918T [n = 1]). It was surprising to find that
in the F2 and F9 families, only proband (F2-II1 and F9-
II3) had the p.C634Y or p.M918T mutation, while his
consanguineous parents and brothers were shown not to
harbor the mutations or MEN2A/MEN2B-related mani-
festations, respectively (Table 1).
Discussion
In this study, the rate of occurrence of MEN2-related
MTC/CCH, PHEO and the mean diagnostic age was
similar to previously reported data [15,16]; however,
MEN2-related HPT was not identified in the current
study, which was different from Zhou et al. [17] re-
ported that the prevalence of Chinese MEN2-related
HPT was 10.8%, which is also lower compared with
Western countries (20%-30%) [4]. The difference may be
related to regional disparities, limited sample size and
racial distribution.
Post-operatively, 17 of 20 (85%) symptomatic patients
presented with residual MTC, metastases, and/or a re-
currence. Five of 6 (83.3%) asymptomatic RET carriers
underwent prophylactic TT had no abnormalities (P <
0.05). MEN2 had an age-related penetrance and metasta-
sis of MTC with a variable intensity of expression. For
the 10% of MEN2-related MTC patients with cervical
LNM who were cured by TT and extensive lymph node
excision, early standard surgery based on diagnostic RET
testing might distinctly improve the cure rate of MEN2-
related MTC [3-5,18,19]. In addition, even the same
family has significant variability in the clinical expression
of disease and development of MTC [for example, F8-
III5, F8-IV5 and F8 other 6 with p.C618Y]. This may
occur by the accumulation of genetic changes that have
a dominant effect on the mutant allele or other affected
factors [20,21].
In 2009, at the 9th meeting of the European Thyroid
Association and Cancer Research Network (ETA-CRN),
there were comments reported to the 2009 ATA guide-
lines that pointed out that timing of prophylactic TT
should be at best synthetically decided by combining the
results of both RET gene testing and the ongoing pre-Ct
level [9]. The timing of TT in RET carriers with a nega-
tive Ct level can be personalized and safely planned
when the stimulated Ct becomes positive. Intrathyroid
MTCs were found when the pre-Ct level was <60 ng/L,
and individualization of surgery in RET carriers with
normal pre-Ct levels may be avoided B-LND (VI) [8,10].
QI et al. [11] also reported that MTC remained located











Histology pTNM LNM Post-Ct (ng/L) Interval time
(years)
F3-III8/F C634Y 41 1744.0 57.9 1.4/3.2 Reject operation - - - - 18
F3-III9/F C634Y 37 206.0 12.2 1.0/0.7 Reject operation - - - - 18
F3-IV1/M C634Y 22 11.8 1.8 -/0.3 Reject operation - - - - 18
F3-IV4/F C634Y 9 9.8 0.7 0.3/0.2 Reject operation - - - - 18
F4-III2/F C634Y 18 118.0 6.8 1.0/1.0 TT + B-VI MTC T1N0M0 0/5 <2.0 17
F5-III4/F C634R 19 24.3 2.9 0.3/0.2 TT MTC T1N0M0 NO <2.0 17
F6-III2/M C634R 21 20.9 2.7 0.5/0.7 TT + B-VI MTC T1N0M0 0/3 <2.0 26
F6-III4/M C634R 21 1769.0 119.6 1.1/1.0 TT + B-VI + R-LND MTC T1N1bM0 20/59 975.0 23
F6-III5/F C634R 19 71.4 3.3 0.5/1.0 TT + B-VI MTC T1N0M0 0/1 <2.0 26
F7-III2/F C618R 26 487.6 25.9 2.0/2.5 Reject operation - - - 17
F8-II2/F C618Y 78 1758.0 106.0 3.0/3.5 Reject operation - - - 19
F8-III5/M C618Y 53 <2.0 2.2 −/− Awaiting surgery - - - 19
F8-IV5/F C618Y 26 5.8 2.0 −/− TT CCH - NO <2.0 19
Note: Ct (basal serum Ct): normal <8.4 ng/L for male and <5.0 for female by FACLIA ; CEA (carcinoembryonic antigen): normal ≤ 5.0 ng/ml; Pre-Ct, pre-surgical Ct;
Post-Ct, post-surgical Ct; TT, total thyroidectomy; B-VI, bilateral level VI lymph node dissection; R/ L -LND, right/ left lymph neck dissection.
*Tumor size was measured by ultrasonography.
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in 17 asymptomatic RET carriers from the Chinese Han
nationality. Here, the 3 patients (F4-III2, F6-III2, and
F6-III5) might have avoided prophylactic B-LND (VI).
More recently, Pelizzo et al. [22] demonstrated that
RET carriers with normal basal Ct levels undergoing
prophylactic TT after testing positive for stimulated Ct
could not always be cured, particularly in 12% of all the
level ATA-B/C RET mutations cases. The threshold for
a definitive cure of MEN2-related MTC still needs to be
empirically determined. The 7 asymptomatic RET carriers
declined surgery or chose a watchful waiting approach,
which offered us the unique opportunity to observe the
natural history of MEN2-related MTC. Thus, it is import-
ant to increase patient awareness to avoid treatment delay.
Furthermore, our observation was also similar to reports






of PHEO to MTC
F1-II4 F C634F 26 Preceding
F2-II1 M C634Y 35 Concomitant
F3-III7 F C634Y 36 Preceding
F4-II3 M C634Y 47 Succeeding
F5-II1 M C634R 34 Succeeding
F5-II7 M C634R 47 Succeeding
F6-III2 M C634R 21 Concomitant
F7-II2 F C618R 40 Succeeding
Note: OPE, open PHEO excision; LPE, laparoscopic PHEO excision; NE (norepinephri
normal, 0 ~ 100 ng/L.and the Q-T interval prolongation of drug toxicity was
remarkable [12,23,24].
Moreover, in the early stages of research, the MEN2A
family (F6, p.C634R) was mistaken for the FMTC family;
however, it was soon shown that the F6-III2 family ac-
companied PHEOs. FMTC is associated with mutations
in codon 634 and is most commonly identified as p.
C634Y, and almost never p.C634R [25]. It has been pre-
viously suggested that it is important to use clinical
screening and deeper genotype-phenotype correlations
in intact pedigree analysis including long-term follow-
up, which may avoid missed diagnoses of PHEOs and/or
HPT and other endocrine adenomas besides the diagno-
sis of MTC (FMTC). It has also been suggested that
family members with the same RET mutation may dis-
play different clinical phenotypes, and the offspring may








246.0/36.3/61.5 L, 3.3 Left OPE 163
399.0/48.2/43.0 R, 2.5 Right OPE 74
827.5/106.0/88.5 R, 4.0 Right OPE 71
657.0/144.2/40.0 L, 2.3 Left LPE 8
1305.0/1270.3/
243.6





667.7/92.5/78.3 R, 2.9 Right LPE 12
69.9/12.6/10.2 L, 3.5 Left LPE 24
681.2/89.4/67.0 L, 2.9 Left LPE 102
ne): normal, 0 ~ 600 ng/L; E (epinephrine): normal, 0 ~ 100 ng/L; DA(dopamine):
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affected by modifying factors from parents or the envi-
ronment, and even by other mechanisms, such as errors
in chromosomal replication during cell division or a sec-
ond somatic mutation [4,26]. Additionally, sufficient pre-
operative preparation before PHEO is necessary and pref-
erential PHEO excision favors the avoidance of burst
hypertensive crisis caused by PHEO during MTC or other
non-PHEO surgical procedures or even death [4,5,26].
Unilateral MEN2A-related PHEO patients usually show
contralateral PHEO over a period of 10 years and malig-
nant MEN2A-related PHEO is rare (0.4%-5.0%) [4,27,28].
Based on a multi-institutional study, Castinetti et al. [28]
recently reported 563 MEN2-related PHEO patients; re-
currence of PHEOs in the same adrenal gland after CSA
was only reported in 4 (3%) of 153 operated glands or in 4
(4%) of 114 patients after 6–13 years. Moreover, 47 of 82
(57%) patients with bilateral PHEO who underwent CSA
did not become steroid-dependent. The CSA is a feasible
surgical strategy for MEN2-related PHEOs, which may
avoid or postpone the need for steroid replacement ther-
apy and the associated risk of an Addisonian crisis [14,28].
The post-operative MEN2-related PHEOs should undergo
follow-up, and monitored long-term for timely diagnosis
and treatment options to prevent or reduce clinical risks
[4,5]. In this study, our results also showed that initially
unilateral CSA was technically safe and feasible, and
may reduce steroid replacement therapy after a second/
contralateral CSA.
The de novo occurrence rate of MEN2A/FMTC was
5.6%-9.0% [29], while in MEN2B > 90% of cases pre-
sented with de novo germline RET mutations [30]. In the
current study, in 2 (F2 [p.C634Y] and F9 [p.M918T]) of
9 families (Figure 1), only 2 probands harbored muta-
tions; all the other consanguineous family members had
no p.C634Y or p.M918T mutations, which suggested
that both patients had de novo mutations or that the
mutations existed in a parental germ cell mosaicism
[31]. The age at which the p.M918T mutation was diag-
nosed in our patient was advanced compared with the
mean age (13 ± 9.3 years) reported by Brauckhoff et al.
[30]. Thus, awareness of the clinical relevance of none-
ndocrine manifestations, timely detection of RET gene
and pre-Ct facilitate an early diagnosis and normalize
surgery to improve the long-term outcome of MEN 2B.
Conclusions
In summary, systematic evaluation of MEN2 patients by
means of integrated screening of RET and pre-Ct levels
and implementation of individualized prophylactic TT
favors a reduction in surgical complications and im-
proves DFS. For advanced MTC, vandetanib provides
novel treatment options. In patients with PHEOs, CSA
can be utilized to preserve adrenocortical function.Competing interests
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